NCT06416800

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

An Open-Label Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Digoxin	Oral; Tablet
DRUG	Rosuvastatin	Oral; Tablet
DRUG	Metformin	Oral; Tablet
DRUG	Povorcitinib	Oral; Tablet
DRUG	Probenecid	Oral; Tablet

Timeline

• Start date: 2024-06-19
• Primary completion: 2025-01-15
• Completion: 2025-01-15
• First posted: 2024-05-16
• Last updated: 2025-02-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study